Bupropion in the Treatment of Methamphetamine Dependence

Status Completed

Clinical Trial Summary

Methamphetamine dependence is a significant drug use disorder in the Midwest. While a number of psychosocial and pharmacological treatments have been studied, no specific treatments for methamphetamine have been identified. This study is a collaborative pre-clinical and clinical partnership examining bupropion in the treatment of methamphetamine dependence.

Clinical Trial Description

Nearly 40% of adults seeking substance use disorders (SUD) treatment in Nebraska report methamphetamine is their drug of choice. In preliminary studies examining bupropion in methamphetamine use, it was well tolerated, reduced craving for methamphetamine and reduced methamphetamine related euphoria. Investigators at the University of Nebraska Medical Center and the University of Nebraska-Lincoln have initiated studies examining bupropion in animals and humans as a potential intervention in addictive disorders. Pre-clinical studies in the Co-Investigator's laboratory were the first to demonstrate the potential utility of bupropion as a pharmacotherapy for methamphetamine use disorders (MUD) while the Principal Investigator studied bupropion as a smoking cessation aid in alcoholics. The primary goal of this study is to establish an interdisciplinary and translational collaboration to test bupropion in persons in treatment for methamphetamine dependence and to inform pre-clinical studies so as to enhance their practical applicability to clinical settings. The pilot clinical study will examine the treatment effect and safety of a 12 week course of bupropion in persons with methamphetamine use disorder. Concurrently, we will examine the efficacy of bupropion on methamphetamine self-administration in animal models which better simulates clinical approaches. ;

Study Design

Related Conditions & MeSH terms

Methamphetamine Use Disorder

Clinical Trial Details

NCT number	NCT00572234
Study type	Interventional
Source	University of Nebraska
Contact
Status	Completed
Phase	N/A
Start date	August 31, 2007
Completion date	May 20, 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04178993` - Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]	Phase 1
Completed	`NCT01982643` - Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder	Phase 1/Phase 2
Completed	`NCT03078075` - Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder	Phase 3
Terminated	`NCT05711862` - The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder	Phase 2
Recruiting	`NCT05322954` - Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder	Phase 1
Recruiting	`NCT05760807` - Intranasal Oxytocin for Methamphetamine Withdrawal in Women	N/A
Recruiting	`NCT04614584` - Mirtazapine and Methamphetamine Drug-drug Interaction Study	Phase 1
Not yet recruiting	`NCT06320366` - Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder	N/A
Recruiting	`NCT05558358` - Deep Brain Stimulation (DBS) for Methamphetamine Use Disorder	Phase 1/Phase 2
Active, not recruiting	`NCT06279273` - A Study for the Risky Decision-making Deficits Among Methamphetamine Dependence Individuals and Treatment	N/A
Active, not recruiting	`NCT04907357` - rTMS for Stimulant Use Disorders	N/A
Completed	`NCT04713124` - A Telephone-delievered Intervention to Reduce Methamphetamine Use	N/A
Active, not recruiting	`NCT04791969` - Intermittent Oral Naltrexone Enhanced With an Ecological Momentary Intervention for Methamphetamine-using MSM	Phase 2
Terminated	`NCT03106571` - Study of Pomaglumetad and Methamphetamine	Phase 1
Recruiting	`NCT06033365` - Beginning Early and Assertive Treatment for Methamphetamine Use Disorder	N/A